Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal

Background: The purpose of inflammatory bowel disease (IBD) treatment is to achieve resolution of symptoms and remission of disease with a minimum of adverse events (AE). Aim: To report AE of different prescriptions used for the treatment of IBD. Material and Methods: Analysis of a registry of patients with IBD held at a private clinic from 1976 to 2013. All used medications, the occurrence and severity of AE were recorded. Results: The records of 346 patients aged 16 to 86 years, 74% with ulcerative colitis, were analyzed. The most commonly type of medications prescribed were 5-aminosalicylates (5-ASAs) in 329 patients (92%), followed by adrenal steroids in 218 (61%). Forty nine AE were recorded in the same number of patents (14%). These were more common in patients with Crohn disease (n = 19, 21%). An univariate analysis, demonstrated that extra-intestinal manifestations, hospitalizations secondary to IBD crisis, requirement of surgery and treatment with steroids, immunosuppressants or biologic agents were significantly associated with the presence of AE. AEs were more common with immunosuppressants, followed by 5-ASAs and steroids. Discontinuation of therapy was required in 79, 100 and 43% of patients taking these medications, respectively. Twenty percent of AEs were severe. Leukopenia and pancytopenia along with alopecia were the most common AEs attributable to azathioprine. Conclusions: The occurrence of AEs in patients with IBD is uncommon. Even inmunosuppressants or biologic agents have a low rate of AE and most of them mild.

Saved in:
Bibliographic Details
Main Authors: Meyer,Lital, Simian,Daniela, Lubascher,Jaime, Acuña,Raúl, Figueroa,Carolina, Silva,Guillermo, Brahm,Javier, Quera,Rodrigo
Format: Digital revista
Language:Spanish / Castilian
Published: Sociedad Médica de Santiago 2015
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100001
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0034-98872015000100001
record_format ojs
spelling oai:scielo:S0034-988720150001000012015-08-11Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinalMeyer,LitalSimian,DanielaLubascher,JaimeAcuña,RaúlFigueroa,CarolinaSilva,GuillermoBrahm,JavierQuera,Rodrigo Crohn Disease Colitis ulcerative Drug-related side effects and adverse reactions Inflammatory Bowel Disease Background: The purpose of inflammatory bowel disease (IBD) treatment is to achieve resolution of symptoms and remission of disease with a minimum of adverse events (AE). Aim: To report AE of different prescriptions used for the treatment of IBD. Material and Methods: Analysis of a registry of patients with IBD held at a private clinic from 1976 to 2013. All used medications, the occurrence and severity of AE were recorded. Results: The records of 346 patients aged 16 to 86 years, 74% with ulcerative colitis, were analyzed. The most commonly type of medications prescribed were 5-aminosalicylates (5-ASAs) in 329 patients (92%), followed by adrenal steroids in 218 (61%). Forty nine AE were recorded in the same number of patents (14%). These were more common in patients with Crohn disease (n = 19, 21%). An univariate analysis, demonstrated that extra-intestinal manifestations, hospitalizations secondary to IBD crisis, requirement of surgery and treatment with steroids, immunosuppressants or biologic agents were significantly associated with the presence of AE. AEs were more common with immunosuppressants, followed by 5-ASAs and steroids. Discontinuation of therapy was required in 79, 100 and 43% of patients taking these medications, respectively. Twenty percent of AEs were severe. Leukopenia and pancytopenia along with alopecia were the most common AEs attributable to azathioprine. Conclusions: The occurrence of AEs in patients with IBD is uncommon. Even inmunosuppressants or biologic agents have a low rate of AE and most of them mild.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.143 n.1 20152015-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100001es10.4067/S0034-98872015000100001
institution SCIELO
collection OJS
country Chile
countrycode CL
component Revista
access En linea
databasecode rev-scielo-cl
tag revista
region America del Sur
libraryname SciELO
language Spanish / Castilian
format Digital
author Meyer,Lital
Simian,Daniela
Lubascher,Jaime
Acuña,Raúl
Figueroa,Carolina
Silva,Guillermo
Brahm,Javier
Quera,Rodrigo
spellingShingle Meyer,Lital
Simian,Daniela
Lubascher,Jaime
Acuña,Raúl
Figueroa,Carolina
Silva,Guillermo
Brahm,Javier
Quera,Rodrigo
Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
author_facet Meyer,Lital
Simian,Daniela
Lubascher,Jaime
Acuña,Raúl
Figueroa,Carolina
Silva,Guillermo
Brahm,Javier
Quera,Rodrigo
author_sort Meyer,Lital
title Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
title_short Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
title_full Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
title_fullStr Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
title_full_unstemmed Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
title_sort eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal
description Background: The purpose of inflammatory bowel disease (IBD) treatment is to achieve resolution of symptoms and remission of disease with a minimum of adverse events (AE). Aim: To report AE of different prescriptions used for the treatment of IBD. Material and Methods: Analysis of a registry of patients with IBD held at a private clinic from 1976 to 2013. All used medications, the occurrence and severity of AE were recorded. Results: The records of 346 patients aged 16 to 86 years, 74% with ulcerative colitis, were analyzed. The most commonly type of medications prescribed were 5-aminosalicylates (5-ASAs) in 329 patients (92%), followed by adrenal steroids in 218 (61%). Forty nine AE were recorded in the same number of patents (14%). These were more common in patients with Crohn disease (n = 19, 21%). An univariate analysis, demonstrated that extra-intestinal manifestations, hospitalizations secondary to IBD crisis, requirement of surgery and treatment with steroids, immunosuppressants or biologic agents were significantly associated with the presence of AE. AEs were more common with immunosuppressants, followed by 5-ASAs and steroids. Discontinuation of therapy was required in 79, 100 and 43% of patients taking these medications, respectively. Twenty percent of AEs were severe. Leukopenia and pancytopenia along with alopecia were the most common AEs attributable to azathioprine. Conclusions: The occurrence of AEs in patients with IBD is uncommon. Even inmunosuppressants or biologic agents have a low rate of AE and most of them mild.
publisher Sociedad Médica de Santiago
publishDate 2015
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100001
work_keys_str_mv AT meyerlital eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal
AT simiandaniela eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal
AT lubascherjaime eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal
AT acunaraul eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal
AT figueroacarolina eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal
AT silvaguillermo eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal
AT brahmjavier eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal
AT querarodrigo eventosadversosenlaterapiafarmacologicadelaenfermedadinflamatoriaintestinal
_version_ 1755988477459038208